Skip to content

Umberto Volpe

3 papers in the library · 82 citations · publishing 2020-2025

Papers

Sort Most recent Most cited

Emerging strategies and clinical recommendations for the management of novel depression subtypes.

Expert Review of Neurotherapeutics April 1, 2025 Stefania Chiappini, Gaia Sampogna, Antonio Ventriglio et al. 17 citations

The phenomenology of depression is characterized by a wide array of emotional, cognitive, and physical symptoms that significantly disrupt an individual's life. Societal changes, driven by technological advancements, economic pressures, environmental concerns including climate change, and shifting cultural norms, have influenced how depression manifests and is understood. These developments...

How does ayahuasca work from a psychiatric perspective? Pros and cons of the entheogenic therapy.

Human Psychopharmacology May 1, 2020 Laura Orsolini, Stefania Chiappini, Duccio Papanti et al. 27 citations

Ayahuasca is a hallucinogenic plant preparation, traditionally consumed in sacred ceremonies by indigenous North-Westerner Amazonian countries like Colombia, Peru, Brazil, and Ecuador. It is fundamental to carefully balance benefits/risks related to the ayahuasca intake, both during ceremonies and experimental settings. The aim is at evaluating and comparing the potential therapeutic benefits...

An Update on Glutamatergic System in Suicidal Depression and on the Role of Esketamine

Current Topics in Medicinal Chemistry January 31, 2020 Domenico de Berardis, Carmine Tomasetti, Maurizio Pompili et al. 38 citations

BACKGROUND: A research on mood disorder pathophysiology has hypothesized abnormalities in glutamatergic neurotransmission, by suggesting further investigation on glutamatergic N-methyl-Daspartate (NMDA) receptor modulators in treating Major Depressive Disorder (MDD). Esketamine (ESK), an NMDA receptor antagonist able to modulate glutamatergic neurotransmission has been recently developed as an...